cyrilzakka/clinical-trials huggingface dataset:
Use of Text Messaging Reminders to Increase FIT Completion Among Patients at the NYU FHCs

The research team will compare the efficacy of targeted text message reminders against currently used phone call reminders at increasing patient completion of fecal immunochemical test (FIT) for colon cancer screening.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients (ages 45-75) eligible for FIT at a Family Health Center clinic (excluding Flatbush locations).

Exclusion Criteria:

* See inclusion criteria.
Mind Body Intervention for COVID-19 Long Haul Syndrome

The present study is a feasibility study in which we will determine if a mind-body program that we have previously developed for chronic back pain can improve the multiple somatic complaints associated with the COVID Long Haul Syndrome.

This study is a pilot and feasibility study to determine if a mind-body program that we have previously developed for chronic back pain can improve the multiple somatic complaints associated with the COVID Long Haul Syndrome in patients without evidence of ongoing tissue injury. We will perform a 12-week intervention consisting of a series of classes which will focus on knowledge therapy, desensitization, emotional expression, and stress reduction.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient ≥ 18 years old
* New symptoms attributed to the post-covid long-haul syndrome (extremity pain, dyspnea, headaches, chest pain, fatigue) occurring after an acute phase of COVID19
* Minimum of at least 12 weeks after the end of the acute phase of COVID-19 infection
* Persistence of symptoms for a least 1 month with no identified other organic etiology
* Score ≥ 3 or more on the SSS-8 score
* Symptoms present for a minimum of 4 days a week
* Willingness to consider mind-body intervention

Exclusion Criteria:

* Patients \< 18 years of age
* Patients \> 60 years of age
* Diagnosed (non-COVID-19) organic disease as cause of pain, such as (but not limited) to malignancy, neurologic disorder (i.e., amyotrophic lateral sclerosis), cauda equina syndrome (note that pain related to disc disease is not an exclusion unless there are neurological impairments).
* Patients with previous severe COVID-19 disease, defined as those who had been admitted to the ICU or have objective evidence of ongoing organ injury (e.g., persistent chest radiographic abnormalities or myocarditis)
* Identified lung or cardiac injury in subjects with chest pain or dyspnea (e.g., chest radiograph abnormalities, cardiac ultrasound showing myocarditis or depressed ejection fraction )
* Patients with a diagnosis of significant psychiatric comorbidities such as schizophrenia or dementia
Conventional Oral Intake vs Delayed Oral Intake With Jejunostomy Feeding After Esophagectomy (JNS Study)

Comparison of nutritional and early surgical outcome between early and delayed oral feeding after esophagectomy for esophageal cancer

Esophageal cancer is a highly aggressive malignancy that metastasizes to the lymph nodes and is associated with a poor prognosis. The 5-year overall survival rate is 40.0 % and the 30-day mortality rate is 1.7 %. Surgical resection is the most effective treatment for localized esophageal cancer; however, esophagectomy is extremely invasive and is associated with high morbidity and mortality rates.

Nutrition is one of the most important factors to consider after esophagectomy in order to reduce surgical mortality. The European Society for Parenteral and Enteral Nutrition guidelines recommend early tube feeding after major gastrointestinal surgery for cancer. Several studies have shown that enteral nutrition is more effective than parenteral nutrition in reducing postoperative complications in postesophagectomy patients. It has been reported that 5 to 7 days are required for anastomosis site healing. Therefore, many centers start oral feeding after esophagectomy on postoperative 7 days after anastomosis site evaluation, and enteral feeding via jejunostomy are maintained for nutritional support. However, the optimal timing for oral feeding after esophagectomy is still under debate.

In our center, the investigators routinely place jejunostomy tube for sufficient enteral feeding after esophagectomy. Before 2014, the investigators started oral feeding 5 to 7 days after esophagectomy and patients were discharged with soft blended diet. After 2014, the investigators changed our postoperative management protocols: 1) the investigators started only liquid diet 5 to 7 days after esophagectomy and maintained this feeding regimen until the first postoperative clinic visit with supplement of enteral feeding by jejunostomy tube. However, no studies have been conducted showing the optimal timing for oral feeding for esophagectomy patients for nutritional support and postoperative care.

The investigators hypothesized that delayed oral feeding after esophagectomy with jejunostomy feeding is superior to conventional oral feeding for nutritional support and early clinical outcome.

Eligibility Criteria:
Inclusion Criteria:

* Patients who planned to undergo esophagectomy with esophageal reconstruction for esophageal cancer for curative purpose
* Patients who can understand the purpose and protocol of the clinical trial

Exclusion Criteria:

* BMI \< 18kg/m2 or BMI \> 25kg/m2
* Patients who needs colon of jejunum for esophageal reconstruction
* Patients who needed enteral feeding before esophagectomy
* Preoperative major organ failure (ex. renal failure requiring renal replacement, hepatic failure)
* Severe metabolic disorder (ex. uncontrolled diabetes mellitus, uncontrolled thyroid disease)
* Other patients who are not suitable for clinical trial
Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)

This study will evaluate the pharmacokinetics of ridaforolimus including the area under the concentration-time curve (AUC\[0-infinity\]) and maximum concentration (Cmax) after administration of a single dose of ridaforolimus in patients with moderate hepatic insufficiency and healthy matched control subjects.


Eligibility Criteria:
Inclusion Criteria:

Hepatic Patients:

* Female patient is of non-child bearing potential
* Apart from hepatic insufficiency with features of cirrhosis, patient is otherwise in good health
* Patient has a diagnosis of chronic stable hepatic insufficiency with features of cirrhosis

Healthy Subjects:

* Female subject is of non-childbearing potential
* Subject is in good health

Exclusion Criteria:

Hepatic Patients and Healthy Subjects:

* Works a night shift and is not able to avoid night shift work during the study
* Has a history of stroke, seizure or major neurological disease
* Has a history of cancer
* Is unable to refrain from or anticipates the use of any prescription or non-prescription drugs during the study
* Consumes excessive amounts of alcohol or caffeine
* Has had major surgery, donated blood or participated in another investigational study in the past 4 weeks
The Effects of Self-Moxibustion Therapy on Subjective Physical Symptoms and Health-related Quality of Life of the Elderly. The Effects of Self-Moxibustion Therapy

There will be significant differences between control and experimental group after the moxibustion intervention as to, subjective physical symptoms and quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Male and female older adults age between 65-85
* Agree to participate and sign for the trail after understanding of study purpose, and method.
* Able to answer for questions by verbally or literally
* Able to participate in 2weeks after follow-up

Exclusion Criteria:

* Having physical disorder such as thyroids, severe heart disease, dietetic mellitus, severe liver disease, allergy
* Subjects who can not attend more than 3 times of intervention session
* Subjects who are eligible by the decision of investigator
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

It's a single arm, open label prospective study, in which the safety and efficacy of autologous CAR-T are evaluated in refractory/relapsed B cell lymphoma patients.

Abbreviation: CAR-T: Chimeric Antigen Receptor T-Cell Immunotherapy.


Eligibility Criteria:
Inclusion Criteria:

1. Age≥18 years, male or female;
2. Karnofsky≥60%；
3. B cell lymphoma patients who are not available for the following treatment: autologous stem cell transplantation, allogeneic stem cell transplantation, or patients with short expected survival (less than 2 years).
4. Patients with CR2 or CR3 and no stem cell transplantation available due to age, disease condition, lack of donors or any other reasons.
5. Patients have had more than 2 combined chemotherapy regimens;
6. Creatinin \<2.5mg/dL；ALT/AST level \<3 times of the maximum of normal range; bilirubin\<3mg/dL；
7. Proper venous condition for leukapheresis, no contraindication for leukapheresis;
8. Patient that could understand and is willing to sign the written consent;
9. Fertile female patient should be willing to take contraceptive measures.
10. Patient that is willing to follow up till at least 2 months after T cell re-transfusion.

Exclusion Criteria:

1. Patients who need ≥15mg prednisone daily due to any cause;
2. Patients with autoimmune disease and need immunosuppressor treatment;
3. Serum creatinin\>2.5 mg/dL；serum AST \>5 times of normal maximum; bilirubin \>3 mg/Dl;
4. FEV1\<2 L，diffusion capacity for carbon monoxide of lung (DLCO) \<40%；
5. Cardiovascular abnormalities that fulfill any of the following: NYHA level III or IV congestive heart failure, severe clinical hypotention; uncontrollable carotid heart disease; or ejection fraction\<35%；
6. Patients with HIV infection, active Hepatitis B or Hepatitis C infection;
7. Patients that have previously received gene therapy of any kind;
8. Obvious clinical encephalopathy or novel neuron function damage;
9. Patients with active infection;
10. Patients had biological treatment, immunotherapy or radiation therapy within 1 month prior to enrollment or are currently under these treatment;
11. Patients who had allergic history to agents of the similar structure as CAR-T;
Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation

The aim of the study is to see how glycaemic control and glycaemic variability affect levels of HIF, VEGF, erythropoietin and cortisol in Paediatric Type 1 diabetics on insulin pump therapy.

The study will have two parts. The first phase will look at all current paediatric type 1 diabetics in Tayside on continuous subcutaneous insulin pump therapy and measure their levels of Hypoxia-Inducible Factor (HIF), Vascular Endothelial Growth Factor (VEGF), erythropoietin and cortisol. This will help answer the question; Does glucose control (as expressed by HbA1c ) effect levels of HIF, VEGF, erythropoietin and cortisol? To our knowledge this will be the first human study comparing how HIF, VEGF, erythropoietin and cortisol are affected by glucose control

The second phase of the trial will chose 10 patients on insulin pump therapy and using a continuous glucose monitor (CGM), monitor their glucose variability over a period of 6 weeks. After this period their levels of HIF, VEGF, erythropoietin and cortisol will again be measured. This will help answer the question of whether there is a relationship between glucose variability and levels of HIF, VEGF, erythropoietin and cortisol. As we know that these factors are stimulated by episodes of hypo and hyperglycaemia, it is hypothesised that these factors will be lower in participants that demonstrate reduced glucose variability. It will be the first study to give detailed information on the relationship between HIF, VEGF, erythropoietin and cortisol and glucose variability.

By using telemedicine sessions during weeks 1, 3 and 5 of the participants wearing CGM we will aim to improve the participant's glucose variability. This will help give further information about glucose variability and the above factors as well as giving further evidence for the use of telemedicine and CGM to improve glycaemic control in adolescent diabetics.

Eligibility Criteria:
Inclusion Criteria:

Phase 1 inclusion:

* Patients with Type 1 Diabetes
* On insulin pump therapy.
* Aged 5 years to 18 years.

Phase 2 inclusion:

* Patents with Type 1 Diabetes
* Diabetes diagnosis for 1 year
* On insulin pump therapy for minimum of six months
* Access to a computer with internet access and telephone
* Agree to wear CGM for 6 weeks
* Aged 12 years to 18 years

Exclusion Criteria:

* Patients not on pump therapy
* Patient less than 5 years and greater than 18 years
* Phase 2 patients been on pump therapy for less than 6 months
* Phase 2 patients without access to internet and telephone.
* Phase 2 patients less than 12 years and greater than 18 years
* Patients who do not have a good understanding of English
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

This is a 12-week, multi-center, randomized, double blind, placebo-controlled, Phase 2 study. The study duration includes a 4-week screening period, a 12-week treatment period, and a 4-week follow-up period. All eligible subjects will be randomly assigned to 1 of 3 treatment arms (HS-10374 Dose 1, HS-10374 Dose 2, and placebo) in an equal ratio.

Eligibility Criteria:
Inclusion Criteria:

1. Male or female subjects between the ages of 18-70 years
2. Diagnosis of plaque psoriasis for at least 6 months
3. Eligible for phototherapy or systemic therapy
4. Plaque covering ≥ 10% of BSA
5. PASI ≥ 12, sPGA ≥3

Exclusion Criteria:

1. Diagnosis of non-plaque psoriasis or drug-induced psoriasis
2. Recent history of infection, history or risk of serious infection
3. Any major illness or evidence of unstable condition of major organ systems including psychiatric disease
4. Any condition possibly affecting the PK process of the study drug
5. Evidence of other skin conditions that would interfere with the evaluation of psoriasis
6. History of hypersensitivity to the ingredients of study drugs, history of anaphylaxis
7. History of lack of response to any therapeutic agent targeted to IL-12, IL-17 or IL-23 at approved doses after at least 3 months of therapy
8. Have received the prohibited treatment during the protocol required washout period
9. Any significant laboratory or procedure abnormalities that might place the subject at unacceptable risk during this study period
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults with Neurofibromatosis Type 1

The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1 pathogenesis and more personalized disease management. The investigators will conduct a GWAS analysis to identify common genetic risk variants associated with the development of cutaneous neurofibromas.


Eligibility Criteria:
Inclusion Criteria:

* Age 40 or older.
* NF type 1 diagnosed using clinical criteria.
* At least one neurofibroma present at time of enrollment.
* Patient able to read and understand consent form (or equivalent translation) and able to give consent.
* Patient able and willing to complete all study procedures.
The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study

We will performe a prospective randomized study to evaluate the effects of the addition of alfuzocine xl 10 mg once a day for the conservative treatment of selected ureteral stones. A total of 60 patients with distal ureteral calculi will randomly divide into two treatment groups: group A (n=30) who will receive only analgetic therapy(Dipyrone)and diclofenac i.m. 75mg and group B (n=30) who will receive the same therapy plus alfuzocin xl (10 mg/daily) for a maximum of 2 weeks.No significant differences will be between the groups for age, gender distribution and mean stone size measured in the single largest dimension at presentation.Randomization will be done only with the patients permission after they had read a summary describing the goals of conservative management and a description of the drugs they would be taking. Potential side effects and complications of the drugs were discussed. The expulsion rate will the primary end-point of this study.


Eligibility Criteria:
Inclusion Criteria:

* Stone in the distal ureter until 1 cm of diameter

Exclusion Criteria:

* Evidence of urinary tract infection or sepsis
* Moderate or severe hydronephrosis
* Acute renal failure
* Ureteral stricture
* Stone with \>1cm of diameter
* Previuos use of alpha blocker
* Pregnancy
* Previuos ureteral endoscopic or open surgery
Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents

This is a diagnostic prospective multicenter study. This study will be conducted in 32 centers of the Société Française des Cancers et Leucémies de l'Enfants et de l'Adolescent (SCFE) in patients with non-Hodgkin lymphoma and treated according to recommendations of the SFCE for each type of non-Hodgkin lymphoma. All patients will have a PET / CT associated with conventional imaging time of remission assessment. Histological examination of residual tumor will be conducted whenever practicable in patients with pathologic residual image on conventional imaging and / or PET / CT. A central review of conventional imaging examinations and PET / CT will be performed independently from each other.

Moreover, whenever possible, patients will have a PET / CT at diagnosis and an early PET / CT (between J8 and J28 according to the type of lymphoma and toxicities due to treatment). The results of the early PET / CT should not lead to treatment modifications.

In case of residual tumor at remission assessment, therapeutics changes as recommended therapeutic protocols will be based on histologic findings and not on the results of PET / CT alone.


Eligibility Criteria:
Inclusion Criteria:

1. All cases of NHL corresponding to one of the following histologies:

   * Burkitt and Burkitt-like (LB)
   * Large cell B-cell lymphoma (LBGC)
   * Primary mediastinal B cell lymphoma (LBPM)
   * Lymphoblastic lymphoma (LL)
   * Anaplastic large cell lymphoma (ALCL)
2. Age \> 2 years and \< 21 years
3. Treated in a SFCE protocol
4. Treated in a center with the possibility of organizing a PET / CT at the time of remission assessment
5. Affiliation to a social security system
6. Possible follow-up for at least 2 years
7. written informed consent signed by the parents or parental authority or the patient himself if he is over 18 years

Exclusion Criteria:

1. relapsing patients
2. Patients with absolute cons-indications to the achievement of a PET scan: pregnancy, incontinence, poorly controlled diabetes or blood glucose\> 10 mmol/l, alterations of superior functions or claustrophobia, making the test impossible.
3. pre-existing or evolving infectious inflammatory disease making PET / CT difficult to interpret
Sucrose Practices for Pain in Neonates Part B

Recent studies show that babies in hospital undergo an average of 4 to 5 painful procedures, such as heel lances, every day. Sucrose (sugar water) has been shown to be effective for reducing babies' pain during painful procedures. Unfortunately, sucrose is not used as often as it could be to reduce babies' pain. This may be due to lack of certainty about the least effective amount of sucrose to use and concerns about the long-term effects of repeated use of sucrose on infant development. Factors within the hospital units where babies receive care may also influence caregivers' decisions to use sucrose. In this research the investigators will conduct two main studies. In the first study the investigators determined the lowest amount of sucrose needed to manage babies' pain effectively. In the second study the investigators will explore (a) if this amount of sucrose can manage pain when it is used repeatedly for all painful procedures while the baby is hospitalized and (b) whether consistent use of sucrose influences the development of babies when they are 18 and 36 months old. During the second study, the investigators will also examine the hospital units where the babies receive care. They will look at staff support for research, time and resources and other factors that promote and prevent sucrose use. The results of these studies will be used to determine the best management of babies' pain during painful procedures in hospitals to achieve the best outcomes.


Eligibility Criteria:
Inclusion:

* less than 32 weeks gestational age at birth
* admitted to the neonatal intensive care unit (NICU)
* expected to have heel lances for routine blood tests
* yet to reach 10 days of life at the time of study enrollment.

Exclusion:

* known hypersensitivity to sucrose, corn, corn products or any component of the formulation
* short-bowel syndrome
* carbohydrate intolerance
* unable to swallow/absent gag reflex (e.g., pharmacologically muscle relaxed, unconscious, or heavily sedated)
Pilot Study on Weight Loss in Guinea Bissau

The purpose of this study is to test two versions a weight loss program potentially suitable for implementation in Africa. A successful method would have widespread application in low-income countries, with the potential to improve world health.

Specific Aim 1 is to conduct a 3-4 month pilot study randomizing participants to two versions of a weight loss program. The program will be implemented in a convenience sample of overweight and obese adults living in Guinea-Bissau and measure changes in body weight loss (primary outcome), adherence to program recommendations including recommended food patterns, blood pressure, eating behavior, physical activity and mood (secondary outcomes). The data will be used to refine the weight loss program and conduct power calculations for a future trial.

Specific Aim 2 is to analyze associations between weight loss, participant demographics and program metrics, to explore reasons for differences in weight loss between participants. Factors to be tested include participant BMI, gender and age, as well as adherence to meal portion recommendations, use of sugar-sweetened beverages and provided foods, and physical activity.

Eligibility Criteria:
Inclusion Criteria:

* Men and women who are overweight or obese (BMI ≥25 kg/m2).
* Want to lose weight, want to enroll in the study and are willing to sign the informed consent form.
* Anticipate being able to meet the study requirements for food habits and study meetings, and anticipate remaining in Bissau for the study duration.
* Between the ages of 20 to 65 years.
* Non-pregnant women, and those who do not intend on becoming pregnant during the course of the study.
* A doctor or nurse has signed a note approving participant in the weight loss intervention after seeing a copy of the handout with title "Instructions for Bissau Weight Loss Pilot Project", and a copy of his/her approval is given to the research staff.

Exclusion Criteria:

* Report food allergies or intolerance or health conditions that would prevent consumption of provided and recommended foods.
* Participation in another concurrent nutrition research study.
* If premenopausal (\<55 years of age), they are pregnant or intend to become pregnant during the course of the study, or are not using a birth control method to prevent pregnancy.